Zydus receives USFDA's nod for Nystatin Ointment USP, Omeprazole and Sodium Bicarbonate Capsules

28 May 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Nystatin Ointment USP, 100,000 units per gram. It is used as an adjunct to treat fungal skin infections and will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group also received the final approval to market Omeprazole and Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg. It is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies


Zydus Lifesciences Share Price

1008.15 10.70 (1.07%)
16-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.20
Dr. Reddys Lab 5820.00
Cipla 1423.85
Zydus Lifesciences 1008.15
Lupin 1659.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.